

Research Article

Theaflavin-3,3'-Digallate Inhibits Erastin-Induced Chondrocytes Ferroptosis via the Nrf2/GPX4 Signaling Pathway in Osteoarthritis

Chao Xu,¹ Su Ni,² Nanwei Xu,³ Guangrong Yin ,⁴ Yunyuan Yu,⁵ Baojun Zhou,⁶ Gongyin Zhao,³ Liangliang Wang,³ Ruixia Zhu,³ Shijie Jiang,³ and Yuji Wang ^{3,6,7}

¹Truma Central, The Affiliated Changzhou No.2 People's Hospital with Nanjing Medical University, 29 Xinglong Alley, Changzhou 213003, China

²Medical Research Center, The Affiliated Changzhou No.2 People's Hospital of Nanjing Medical University, 29 Xinglong Alley, Changzhou 213003, China

³Department of Orthopedics, The Affiliated Changzhou Second People's Hospital of Nanjing Medical University, Changzhou Second People's Hospital, Changzhou Medical Center, Nanjing Medical University, 29 Xinglong Alley, Changzhou 213003, China

⁴Graduate School of Dalian Medical University, 9 West Section, Shunnan Road, Dalian 116044, China

⁵The Affiliated Changzhou No.2 People's Hospital of Nanjing Medical University, 29 Xinglong Alley, Changzhou 213003, China

⁶Department of Orthopedics, The Third Affiliated Hospital of Gansu University of Chinese Medicine, 222 Silong Road, Baiyin 730900, China

⁷Department of Orthopedic Surgery and Biochemistry & Molecular Biology, Mayo Clinic, Rochester, MN, USA

Correspondence should be addressed to Yuji Wang; 13775221377@139.com

Received 15 June 2022; Revised 20 October 2022; Accepted 1 November 2022; Published 17 November 2022

Academic Editor: Demetrios Kouretas

Copyright © 2022 Chao Xu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

There is evidence that osteoarthritis (OA) is associated with ferroptosis which is a kind of lipid peroxidation-related cell death. Theaflavin-3,3'-digallate (TF3), a polyphenol compound extracted from black tea, possesses antioxidative and anti-inflammatory properties, but its effects on chondrocyte ferroptosis in osteoarthritis (OA) remain unclear. Our present study aims at exploring the protective role and underlying mechanisms of TF3 against erastin-induced chondrocyte ferroptosis in OA. In human primary chondrocytes treated with erastin alone or combined with different doses of TF3, cell viability was assessed by MTS. Ferroptosis-related proteins, including Gpx4, HO-1, and FTH1, were detected by western blot. The levels of lipid peroxidation and Fe²⁺ were determined by fluorescence staining. Meanwhile, the change of related proteins in the Nrf2/Gpx4 signaling pathway was determined by western blot. siRNA-mediated Nrf2 knockdown and the Gpx4 inhibitor RSL3 were used to explore molecular mechanisms for TF3-induced ferroptosis in OA chondrocyte. The magnetic resonance imaging (MRI), HE staining, Masson's staining, and immunohistochemistry were used to evaluate articular cartilage damages in the rat OA model. The results showed that Gpx4 expression was markedly downregulated in the chondrocytes of OA patients. TF3 reversed erastin-induced ferroptosis of human cultured chondrocytes, lipid ROS, and Fe²⁺ production in mitochondria. Moreover, the expression of Gpx4, HO-1, FTH1, and Nrf2 was markedly induced by TF3 in the erastin-treated chondrocytes. The anti-ferroptotic effect of TF3 was related to enhance Nrf2/Gpx4 signaling pathway. Finally, TF3 inhibited OA progression by alleviating *in vivo* cartilage damage related to chondrocyte ferroptosis. Thus, TF3 significantly inhibits chondrocyte ferroptosis by activating the Nrf2/Gpx4 signaling pathway, suggesting that TF3 serves as a potential therapeutic supplement for OA treatment.

1. Introduction

Osteoarthritis (OA), a chronic degenerative disease, has become a notable cause of disability in elderly patients. The incidence of OA among people over 75 years old is approximately 70% to 90%, and more than 100 million people worldwide suffer from OA [1]. The clinical manifestations of OA are joint pain, swelling, joint deformities, and restricted mobility [2]. Cartilage degeneration, destruction, and osteophyte formation are the main pathological features of OA [2]. Many physiological processes contribute to the development of OA, such as pyroptosis, apoptosis, and autophagy of chondrocytes. Chondrocytes undergo ferroptosis during OA, and that ferroptosis contributes to the progression of the disease [3]. Thus, inhibition of chondrocyte ferroptosis promises a potential OA therapy.

Ferroptosis is a type of iron-dependent lipid peroxidation-related cell death process that requires the accumulation of iron-dependent cellular active oxidation products [4]. Ferroptosis can lead to the progression of various diseases, including ischemia–reperfusion injury [5], neurodegenerative diseases [6], and tumors [7]. Iron is essential for cell physiological and biochemical processes, including participation in oxygen transport, DNA and ATP synthesis, and the tricarboxylic acid (TCA) cycle [8, 9]. In addition, Fe^{2+} promotes the lipid peroxidation of saturated fatty acids and the oxidative phosphorylation of mitochondria [10, 11]. The oxidative reaction induced by iron deposition leads to oxidative stress, causing protein, nucleic acid, and liposome damage directly or indirectly, which gives rise to cell damage or ferroptosis [12]. Firstly, liposome peroxidation causes damage to cell membrane composition and structure [13, 14]. In addition, liposome peroxidation produces a large amount of lethal reactive oxygen species (ROS), malondialdehyde (MDA), and peroxide dismutase (SOD), and these products can react with DNA or protein, further exerting toxic effects [15]. Glutathione peroxidase 4 (Gpx4), a lipid repair enzyme, is regulated by glutathione (GSH), which has been illustrated to block ferroptosis by reducing lipid peroxidation products and lethal reactive oxygen species accumulation [16, 17]. Activation of the antioxidant enzyme Gpx4 may have a potential to suppress ferroptosis.

Theaflavin-3,3'-digallate (TF3), a polyphenol compound extracted from black tea [18], has attracted medical attention because of its extensive pharmacological effects, such as anti-cancer, antiviral, antioxidant, anti-inflammatory [19], and immunomodulatory [20] effects. A previous study indicates that TF3 regulates the expression of copper transporter 1 and GSH through the wnt/ β -catenin pathway to inhibit ovarian cancer [21, 22]. TF3 inhibited RANKL-induced osteoclast formation in bone marrow-derived macrophages (BMMs) in animal models [23]. In addition, TF3 could activate plasma kallikrein expression, reduce the deposition of fat and antagonize the oxidative damage induced by H_2O_2 in hepatocytes [24]. In human chondrocytes, theaflavins (TFs) reduced oxidative stress-induced apoptosis and modulated AKT activation [25]. Moreover, ferroptosis is affected by multiple signaling pathways in cells [26]. The Keap1/

Nrf2 pathway is involved in glioma cell proliferation and ferroptosis [27]. MAPK/ERK/p38 [28, 29], Stat3/Nrf2/Gpx4 [30, 31], and ALK4/5 [32] signaling pathways are critical for ferroptosis induction. Despite these exciting discoveries, it remains that the role of TF3 in OA chondrocyte ferroptosis and related signaling pathway is far from elucidated. In this study, we aimed to further explore the role of TF3 in OA chondrocyte ferroptosis and elucidate its underlying mechanisms.

2. Materials and Methods

2.1. Collection of Subjects. Informed consent was received from all individual participants (including OA patients and trauma patients with femur fractures) in this study, and the sample (cartilage tissue) collection was approved by the Medical Ethical Committee of Changzhou No. 2. People's Hospital.

2.2. Reagents. TF3 was purchased from Shanghai YuanYe Biotech. Co., Ltd. (Shanghai, China), with an approximate purity of 98%. TF3 was dissolved in ethyl alcohol and diluted with DMEM-F12 for experiments. Collagenase II (Worthington Biochemical Corp., Lakewood, NJ, USA) was dissolved in DMEM at 2.5 mg/ml to digest the articular cartilage. Erastin, a ferroptosis activator acting on mitochondrial voltage-dependent anion channels (VADC), was purchased from Sigma–Aldrich, reconstituted in DMSO at 5 mM and stored at -20°C in the darkness. RSL3, a Gpx4 inhibitor, and deferoxamine (DFO), a ferroptosis inhibitor, were purchased from Selleckchem (Houston, TX, USA).

2.3. Isolation and Culture of Human Chondrocytes. Cartilage tissue specimens were obtained from the medial condyle (severely damaged joint areas) of the femur of OA patients and trauma patients with femur fracture during joint replacement surgery in the Affiliated Changzhou No. 2 People's Hospital of Nanjing Medical University. The OA severity was determined using weight-bearing anteroposterior radiographs of the affected joints according to the Kellgren and Lawrence (KL) classification (all the KL classification of all OA patients was at grade 3 in our study). These female patients with femur fractures had healthy joints. The clinical characteristics (age, gender, and disease duration) of all participants were shown in Table 1. All articular cartilage tissues were carefully minced and digested with collagenase II in serum-free Dulbecco's modified Eagle's medium (DMEM) (Gibco BRL, Grand Island, NY, USA), filtered through a $70\ \mu\text{m}$ cell strainer (BD, Durham, NC, USA), and extensively washed with blank DMEM/F12. Finally, chondrocytes were cultured in DMEM/F12 containing 10% fetal bovine serum (Gibco BRL, Grand Island, NY, USA), $50\ \mu\text{g}/\text{mL}$ ascorbic acid (AA, Sigma), 100 U of penicillin, and $100\ \mu\text{g}/\text{mL}$ streptomycin. When adherent cell confluence reached 90%, chondrocytes were separated. Passages 2 to 3 were used in our experiments.

2.4. MTS Cytotoxicity Assays. MTS (Promega, Madison, WI, USA) cytotoxicity assays were applied to assess human OA chondrocyte cytotoxicity and viability. A total of 5×10^3 cells were plated in 96-well plate and allowed to attach

TABLE 1: Characteristic of subjects investigated.

Characteristics	OA	TRUMA
Total number of subjects	20	20
Age ^a , years	65	65
25th percentile	62	61
75th percentile	72	70
Number of female/male subjects	20/0	20/0
Disease duration ^a , years	4.8	—
25th percentile	2.5	—
75th percentile	6.5	—

^aMedian.

overnight. TF3 and erastin were used to treat chondrocytes. After treatment, 10 μ l of MTS solution reagent was pipetted into each well of a 96-well plate. Then, the plate was incubated at 37°C for 2 hours without light, and the absorbance at 490 nm was recorded with an absorbance microplate reader (Elx808™ Bio-Tek Instruments, Winooski, VT).

2.5. RT-PCR Analysis. Chondrocytes were treated in different conditions, and then total RNA was extracted with the NucleoSpin RNA Kit (MN, Düren, Germany) according to the instructions. After the obtained RNA was quantified, 1 μ g of total RNA was taken, and reverse transcription was performed using the High Capacity cDNA Reverse Transcription kit (Applied Biosystems, Foster City, CA, USA) according to the instructions. SYBR® Select Master Mix (Applied Biosystems, Austin, TX, USA) was used to perform quantitative PCR to detect Gpx4 mRNA expression in chondrocytes, and GAPDH was selected as the internal reference. The specific primer sequences were designed by Shenggong Biotech. Co., Ltd. (Shanghai, China) and are as follows: Gpx4, 5'-GAGGCAAGACC-GAAGTAACTAC-3' (forward) and 5'-CCGAACTGGTTACACGGGAA-3' (reverse); GAPDH, 5'-CTGGGCTACAC TGAGCACC-3' (forward) and 5'-AAGTGGTCGTTGAG GGCAATG-3' (reverse). Quantitative PCR was performed using the ViiATM 7 real-time PCR system. The comparative threshold cycle method was used to determine the relative quantification of mRNA.

2.6. Western Blot Analysis. Cultured chondrocytes were lysed on ice with RIPA buffer (Beyotime Biotechnology, Shanghai, China) and boiled for 5 min at 99°C. A 15% polyacrylamide gel was used to separate proteins, and then proteins were transferred to a polyvinylidene fluoride (PVDF) membrane (Millipore Corp., Danvers, MA, USA). The following rabbit polyclonal antibodies were purchased from Cell Signaling Technology (Danvers, MA, USA), ABclonal Technology (Wuhan, China), and Proteintech (Wuhan, China). The information of antibodies is listed in Table S1. Rabbit polyclonal antibodies were used to detect human proteins related to the Nrf2/Gpx4 signaling pathways and ferroptosis-related proteins Slc7a11, FTH1, and HO-1. The human β -actin antibody was used as an internal control

for protein loading, and relative expression levels were quantified using Quantity One software.

2.7. Propidium Iodide Stain. After different treatments, 2 μ l of PI solution reagent (Vazyme Biotech Co., Ltd., Nanjing, China) was pipetted into each well plate. Then, the plate was incubated at room temperature for 5 minutes without light and was observed under a fluorescence microscope (Nikon Eclipse Ti, Japan).

2.8. Nuclear Protein Extraction. Nuclear protein was extracted using a nuclear protein extraction kit (Beyotime, China, P0028) according to the manufacturer's protocol. The human lamin B and β -actin antibodies were used as the internal controls for protein loading, and relative expression levels were quantified using Quantity One software.

2.9. Lipid ROS Assay. Chondrocytes were incubated with 5 μ M C11-BODIPY^{581/591} (Thermo Fisher Scientific, USA) fluorescent probe in a serum-free medium for 30 min at 37°C in the dark and washed three times with PBS according to the modified protocol. The green and red fluorescence signals were observed under a fluorescence microscope (Nikon Eclipse Ti, Japan). The fluorescence intensity was quantified using Image Pro Plus 6.0 software.

2.10. Fe²⁺ Detection. The Fe²⁺ content of different groups was analyzed using a Mito-Ferrogreen Assay Kit (Dojindo, Shanghai, China) according to the manufacturer's instructions. The Fe²⁺-positive cells were green under fluorescence microscopy (Nikon Eclipse Ti, Japan), and the fluorescence intensity was quantified using Image Pro Plus 6.0 software.

2.11. Si-RNA Transfection Analysis. The Nuclear factor erythroid 2-related factor 2 (Nrf2) siRNA sequence was purchased from Beyotime Biotechnology (Shanghai, China) and the siRNA sequences are as follows: Si-Nrf2#1: 5'-CATTGATGTTTCTGATCTA-3' Si-Nrf2#2: 5'-GGTTGAGACTA CCATGGTT-3'; Si-Nrf2#3: 5'-GAGGCAAGATATAGAT CTT-3'. Transfections were performed according to the manufacturer's instructions. The group of chondrocytes transfected with an empty vector was used as the negative control.

2.12. Animal Experiments. In total, 25 male SD rats, weighing 150 to 200 g, were purchased from Cavens Experimental Animal Co. Ltd. (Changzhou, China). All rats were randomly divided into five groups: control, OA, OA + Erastin, OA + Erastin+TF3, and OA + Erastin+DFO. DFO, an effective iron chelator, has been used to inhibit ferroptosis in various degenerative disease models [33]. In an OA animal model, DFO delayed the progression of primary OA. Therefore, DFO was selected as a positive control for animal experimental treatment [34]. The OA model was successfully established by medial meniscus destabilization (DMM) surgery. TF3 (1 mg/kg), erastin (1 mg/kg), or DFO (1 mg/kg) were injected into the articular cavity twice a week, and the rats were sacrificed six weeks later. The progression of OA was evaluated using the Osteoarthritis Research Society International (OARSI) scored by two blinded investigators. The effects of TF3 and DFO




FIGURE 1: The Gpx4 expression was downregulated in cultured chondrocytes from OA patients. (a) Gpx4 protein expression in chondrocytes from trauma patients (HC1 to HC4: chondrocytes from 4 different trauma controls) and OA patients (OA1 to OA4: OA chondrocytes from 4 different OA patients). (b) The mRNA levels of Gpx4 in the chondrocytes from trauma patients (as healthy control, $n = 20$) and OA patients ($n = 20$) were examined by qPCR. Data were compared by unpaired t -test, $**p < 0.01$. HC: healthy control; OA: osteoarthritis; Gpx4: glutathione peroxidase 4.

treatments were measured by morphological analysis and magnetic resonance imaging (MRI) examination. The animal study proposal was approved by the Animal Care Committee of Nanjing Medical University. All animal experimental procedures were performed in accordance with the Regulations for the Administration of Affairs Concerning Experimental Animals approved by the State Council of the People's Republic of China.

2.13. MRI Examination. Six weeks after the model operation, cartilage damage was examined by MRI.

2.14. Immunohistochemical Staining and Histomorphometric Measurements. Tibial and femoral tissues were separated and fixed in 10% formalin, decalcified in 10% ethylenediaminetetraacetic acid (EDTA) for 3 weeks after washing with water, and then dehydrated in graded alcohols. Specimens were embedded in paraffin and cut into $5 \mu\text{m}$ serial sections. 3 sections per rat were analyzed, and all sections were from medial femoral condyles. H_2O_2 (3%) and BSA (5%) were used to block endogenous peroxidase activity and nonspecific binding sites, respectively. The Gpx4 primary antibodies were incubated overnight at 4°C . Next, the appropriate HRP-conjugated secondary antibody was added to the sections for incubation and counterstaining with haematoxylin at room temperature. Each glass slide was stained with HE and Masson's staining according to the manufacturer's instructions.

2.15. Statistical Analysis. Statistical analyses were performed using Prism8 (GraphPad Software, San Diego, CA, US). Unpaired Student's t -test was used for two groups; one-way ANOVA was used for more than two groups, and the Mann-Whitney U test was used for ranked data analysis. All quoted p values were 2-tailed, and those less than 0.05 were considered statistically significant.

3. Results

3.1. The Expression of Gpx4 in Cultured Chondrocytes from OA Patients. We examined the expression of Gpx4 in cultured chondrocytes isolated from articular cartilage tissues

derived from OA patients and trauma patients with femur fractures. The results showed that the mRNA and protein expression levels of Gpx4 were decreased in OA chondrocytes compared with chondrocytes from trauma patients (Figures 1(a) and 1(b)), suggesting that the ability of chondrocytes to clear ROS was largely compromised in OA.

3.2. TF3 Shows No Significant Cytotoxicity to Chondrocytes at Appropriate Concentrations. The molecular structure of TF3 was shown in Figure 2(a). To evaluate the dose effect of the ferroptosis activator erastin, cultured OA chondrocytes were incubated with five different concentrations of erastin (1, 2, 5, 10, and $20 \mu\text{M}$) and the solvent DMSO as a control. As demonstrated in Figure 2(b), chondrocyte viability was decreased in a dose-dependent manner. Notably, when chondrocytes were treated with $5 \mu\text{M}$ erastin, chondrocyte ferroptosis was successfully induced with a reduced viability after 12 hrs. Therefore, a $5 \mu\text{M}$ concentration of erastin was used to induce ferroptosis in the subsequent experiments. Next, we used different concentrations of TF3 (5, 10, 15, 30, and $60 \mu\text{M}$) to treat OA chondrocytes for 12 hrs or 24 hrs. The MTS results showed that TF3 did not significantly affect chondrocyte viability at different concentrations (Figures 2(c) and 2(d)), suggesting that TF3 had no significant cytotoxicity to culture chondrocytes at given concentrations.

3.3. TF3 Reverses Erastin-Induced Cell Viability in Cultured OA Chondrocytes. To evaluate the protective role of TF3, chondrocytes were pretreated with $15 \mu\text{M}$ or $30 \mu\text{M}$ TF3 for 2 hrs before 24 hrs of incubation with $5 \mu\text{M}$ erastin. Both concentrations of TF3 (15 and $30 \mu\text{M}$) markedly rescued erastin-induced chondrocyte viability, with a more significant effect at a higher concentration of TF3, as shown in Figure 2(e), suggesting a protective role of TF3 in erastin-induced chondrocyte.

3.4. TF3 Inhibits the Erastin-Induced ROS Level in OA Chondrocytes. Next, we used different concentrations of erastin to induce ferroptosis in OA chondrocytes, used PI staining to visualize the chondrocyte ferroptosis and a




FIGURE 2: TF3 reverses erastin-induced chondrocyte viability. (a) Chemical structure diagram of TF3. (b) Chondrocytes were treated with different concentrations of erastin (1 μM , 2 μM , 5 μM , 10 μM , and 20 μM) for 24 hrs. (c, d) Chondrocytes were treated with different concentrations of TF3 for 12 hrs or 24 hrs. (e) Chondrocytes were pretreated with TF3 (15 μM /30 μM) for 2 hours and then stimulated with erastin (5 μM) for 24 hrs. The results are presented as the mean \pm SD of three independent experiments, and statistical significance was determined by one-way ANOVA. * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$. NC: negative control.

C11BODIPY fluorescent probe to detect intracellular ROS and lipid ROS levels, and examined ferroptosis-related protein expression by western blot. PI staining showed that chondrocyte ferroptosis was significantly promoted by erastin (Figures 3(a) and 3(b)). Both intracellular ROS and lipid ROS were accumulated in erastin-treated chondrocytes as reflected by the intensity of green fluorescence

(Figures 3(c) and 3(d)). However, TF3 reduced the levels of intracellular ROS and lipid ROS and the number of PI-positive chondrocytes (Figures 3(a)–3(d)). Western blot indicated that erastin decreased ferroptosis-related protein expression, ferritin heavy chain 1 (FTH-1), and Gpx4 (Figures 3(e) and 3(f)). In addition, TF3 reversed the expression of FTH-1, Gpx4, and Slc7a11 (Figure 3(g) and




FIGURE 3: Continued.




FIGURE 3: The protective effect of TF3 on erastin-induced ferroptosis in cultured OA chondrocytes. (a) Chondrocyte ferroptosis was detected by PI staining; representative images are shown. (b) Quantitative analysis of PI positive percentage. (c) Lipid ROS levels were determined by fluorescent staining; representative images are shown. (d) Quantitative analysis of lipid ROS levels in chondrocytes. (e) Levels of FTH-1 and Gpx4 in chondrocytes after stimulation by different concentrations of erastin (5 μ M, 10 μ M, 20 μ M) for 24 hrs were measured by western blotting. (f) Quantitative analysis for expression of FTH-1 and Gpx4 in erastin-treated chondrocytes. (g) Chondrocytes were pretreated with TF3 for 2 hours and then stimulated with erastin (5 μ M) for 24 hrs. The levels of FTH-1, Gpx4, and Slc7a11 in erastin-treated chondrocytes pretreated with TF3. (h) Quantitative analysis for the expression of FTH-1, Gpx4, and Slc7a11 in erastin-treated chondrocytes pretreated with TF3. (i) The Fe²⁺ level in mitochondria was examined by Mito-Ferrogreen staining; representative images are shown. (j) Quantitative analysis of Fe²⁺ level. The results are presented as the means \pm SD of three independent experiments, and statistical significance was determined by one-way ANOVA. * p < 0.05, ** p < 0.01, *** p < 0.001, # p < 0.0001; n.s.: no significant difference. NC: chondrocytes were cultured in DMEM-F12 for 24 hrs. Erastin: chondrocytes were treated with 5 μ M erastin for 24 hrs. Erastin+15TF3/Erastin+30TF3: chondrocytes were pretreated with different concentrations of TF3 (15 μ M and 30 μ M) for 2 hrs and then incubated with erastin for 24 hrs. FTH1: ferritin heavy chain 1; Gpx4: glutathione peroxidase 4; Slc7a11: light chain subunit of the cystine/glutamate anticarrier.

Figure 3(h)). Together, these observations indicated that TF3 inhibits chondrocyte ferroptosis by improving the Gpx4 expression suppressed by erastin.

3.5. TF3 Promotes Iron Metabolism in Cultured OA Chondrocytes. Abnormal iron metabolism is another contributor to ferroptosis, and iron deposits are found in OA [35]. Ferrogreen was used to detect the Fe²⁺ level. The results showed that Fe²⁺ was accumulated in chondrocytes treated with erastin. In contrast, TF3 reduced the accumulation as reflected by the intensity of green fluorescence (Figures 3(i) and 3(j)). In addition, Fe²⁺ was stored in FTH1, and FTH1 participated in iron metabolism progression. Western blot results showed that TF3 upregulated the expression of FTH1 in the erastin-treated chondrocytes (Figure 3(g)).

Taken together, TF3 improves iron metabolism in OA chondrocytes.

3.6. TF3 Protects Chondrocytes from Ferroptosis via the Nrf2/Gpx4 Signaling Pathway. To further investigate molecular mechanisms for TF3 in protecting chondrocytes from ferroptosis, we detected change of the signaling pathway-related proteins. TF3 significantly increased Nrf2, Keap1, p-MEK1/2, and p-Erk1/2 expressions in the total cell lysate (Figures 4(a) and 4(b)). Next, we separated the nucleus component from cytoplasm and carried out western blot analysis. A significantly increased expression of Nrf2 was observed in the nucleus and the cytoplasm upon TF3 treatment (Figures 4(c) and 4(d)). Then, we knockdown Nrf2 expression by using small interfering RNA (si-RNA) and




FIGURE 4: TF3 activates the Keap1/Nrf2 signaling and the MEK1/2/ERK1/2 signaling pathways in chondrocytes stimulated with erastin. (a) The levels of Nrf2, Keap1, p-MEK1/2, MEK1/2, p-ERK1/2, and ERK1/2 in chondrocytes after stimulation were examined by western blotting; representative bands are shown. (b) Quantitative analysis for the expression of Nrf2, Keap-1, p-MEK1/2, and p-ERK1/2 in chondrocytes. (c) The nucleus and cytoplasm expression levels of Nrf2 in chondrocytes were determined by western blotting; representative bands are shown. (d) Quantitative analysis for the nucleus and cytoplasm expression levels of Nrf2. The human lamin B and β -actin antibodies were used as the internal controls for nucleus and cytoplasm protein loading, respectively. The data are presented as the mean \pm SD of three independent experiments, and statistical significance was determined by one-way ANOVA. * $p < 0.05$, ** $p < 0.01$. NC: chondrocytes were cultured in DMEM-F12 for 24 hrs. Erastin: chondrocytes were treated with 5 μ M erastin for 24 hrs. Erastin+15TF3/Erastin+30TF3: chondrocytes were pretreated with different concentrations of TF3 (15 μ M, 30 μ M) and then incubated with erastin. Nrf2: nuclear factor erythroid 2-related factor 2.

observed the effect of TF3 on chondrocyte ferroptosis. The effectiveness of knockdown was confirmed in Figure 5(a). We observed that the combination treatment of erastin with TF3 significantly increased the PI-positive cell percentage, levels of lipid ROS, Fe^{2+} in mitochondria in the si-Nrf2 chondrocytes compared with the si-NC chondrocytes (Figures 5(b)–5(g)). On the contrary, the expression of ferroptosis-related protein (Slc7a11, Gpx4, FTH1, and HO-1) was markedly decreased in erastin+TF3+si-Nrf2 group in comparison with the erastin+TF3+si-NC group (Figures 5(h) and 5(i)). Moreover, we further evaluated the TF3 protective role of Gpx4 by applying the Gpx4 inhibitor RSL3 to cultured OA chondrocytes for 2 hrs. The MTS results showed that TF3 failed to improve chondrocyte viability in the presence of RSL3 (10 μ M) (Figure 6(a)). Meanwhile, TF3 did not decrease PI-positive chondrocytes number

(Figures 6(b) and 6(c)), lipid ROS (Figures 6(d) and 6(e)), and Fe^{2+} level in mitochondria (Figures 6(f) and 6(g)). However, TF3 partly reversed the expression of FTH1, Gpx4, HO-1, and Slc7a11 (Figures 6(h) and 6(i)). Collectively, these data suggested that the Nrf2/Gpx4 signaling pathway is involved in TF3-regulated chondrocyte ferroptosis.

3.7. TF3 Attenuates Cartilage Degradation and Increased Proteoglycans and Gpx4 Expression in a Rat OA Model. To further explore the role of TF3-regulated ferroptosis *in vivo*, we established a rat OA model. The gross morphological images of the rat's knee were shown in Figure 7(a). In the OA group, the articular surface was rough and ulcerated. The degree of cartilage joint injuries was more serious in OA+erastin group, while the cartilage joint injuries were repaired in the OA+erastin+TF3 group to some extent.




FIGURE 5: Continued.




FIGURE 5: Knockdown of Nrf2 reverses TF3-antiferroptosis effects in chondrocytes stimulated with erastin. (a) The expression of Nrf2 in chondrocytes with si-RNA treatments was examined by western blotting. (b) Chondrocyte ferroptosis was detected by PI staining; representative images are shown. (c) Quantitative analysis of PI positive percentage. (d) Lipid ROS levels were evaluated by fluorescent staining; representative images are shown. (e) Quantitative analysis of lipid ROS levels in chondrocytes. (f) The Fe^{2+} levels in mitochondria were detected by Mito-Ferrogreen staining; representative images are shown. (g) Quantitative analysis of Fe^{2+} level. (h) The levels of Slc7a11, Gpx4, FTH-1, HO-1, and Keap1 in chondrocytes after stimulation were examined by western blotting; representative images are shown. (i) Quantitative analysis for the expression of Slc7a11, Gpx4, FTH-1, HO-1, and Keap1 in chondrocytes. Chondrocytes were pretreated with TF3 for 2 hours and then transfected with Nrf2 si-RNA and stimulated with erastin ($5 \mu\text{M}$) for 24 hours. The data are presented as the mean \pm SD of three independent experiments, and statistical significance was determined by one-way ANOVA. * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$, # $p < 0.0001$; n.s.: no significant difference.

The MRI results illustrated that the degree of articular surface cartilage destruction in OA + erastin group was also more serious than that of in the OA group, while the degree of articular cartilage destruction was significantly alleviated in the TF3 treatment groups (Figure 7(b)). Furthermore, we also observed that cartilage damage was reversed after TF3 treatment, as showed by HE staining (Figure 7(c)) and OARSI score (Figure 7(d)). These observations suggested that articular cartilage damage might be repressed by TF3.

The proteoglycans in the cartilage were gradually lost as OA progresses. We used Masson's staining to assess the changes of proteoglycans in cartilage. Intra-articular injection of 1 mg/kg TF3 significantly reversed the proteoglycans levels in the cartilage, as assessed in Figure 8(a). Immunohistochemistry staining showed that the number of Gpx4-positive chondrocytes was reduced in the OA + erastin group, but significantly increased in OA + erastin+TF3

group (Figures 8(b) and 8(c)). In summary, TF3 alleviates OA progression by Gpx4-mediated inhibition of chondrocyte ferroptosis in a rat OA model.

4. Discussion

In this study, we found that TF3 delayed the progression of OA and protected chondrocytes from ferroptosis via modulation of the Nrf2/Gpx4 signaling pathway. Currently, non-steroid anti-inflammatory drugs (NSAIDs) is prescribed for treatment of OA. While it affords some protection to ferroptosis, it has noticeable side effects. Researchers have reported drug-drug interactions resulting in liver damages [36]. In erastin-induced chondrocyte ferroptosis, TF3, at nontoxic concentrations, reversed cell viability in a dose-dependent manner, suggesting that TF3 may have the fewer





FIGURE 6: Continued.



(i)

FIGURE 6: TF3 fails to reverse RSL3-induced ferroptosis in chondrocytes. (a) Chondrocyte viability was measured by MTS. (b) Chondrocyte ferroptosis was detected by PI staining; representative images are shown. (c) Quantitative analysis of PI positive percentage. (d) Lipid ROS levels were evaluated by fluorescent staining; representative images are shown. (e) Quantitative analysis of lipid ROS levels in chondrocytes. (f) The Fe^{2+} levels in mitochondria were detected by Mito-Ferrogreen staining; representative images are shown. (g) Quantitative analysis of Fe^{2+} level. (h) The levels of FTH-1, Gpx4, HO-1, Slc7a11 and Nrf2 were measured by western blot; representative bands are shown. (i) Quantitative analysis for the expression of FTH-1, Gpx4, HO-1, Slc7a11, and Nrf2 in chondrocytes. The quantitative results are presented as the means \pm SD of three independent experiments, and statistical significance was determined by one-way ANOVA. * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$; n.s.: no significant difference. NC: chondrocytes were cultured in DMEM-F12 for 24 hrs. RSL3: chondrocytes were pretreated with TF3 for 2 hours and then stimulated with RSL3(10 μM) for 12 hrs. FTH-1: ferritin heavy chain 1; Gpx4: glutathione peroxidase 4; HO-1: heme oxygenase-1; Slc7a11: light chain subunit of the cystine/glutamate anticarrier; Nrf2: nuclear factor erythroid 2-related factor 2.

side effects and plays a protective role in OA chondrocyte ferroptosis.

Erastin, a ferroptosis inducer, can reduce glutathione levels by directly inhibiting cystine/glutamate antiporter system Xc- activity and activating the ferroptotic response [37], increasing ROS and iron accumulation further inducing ferroptosis [38]. Thus, we chose erastin to induce chondrocyte ferroptosis. Lipid peroxidation and iron accumulation were key factors in ferroptosis. Gpx4, an antioxidant agent, was negatively correlated with lipid peroxidation and showed protective effect on ferroptosis. Studies have indicated that the expression of Gpx4 was decreased in synovial fluid from the patients with OA and rheumatoid arthritis (RA) [39, 40], which is consistent with our findings. Its inhibition blocks intracellular iron metabolism, resulting in lipid peroxidation products and ROS accumulation and thus accelerating ferroptosis progress [41]. Additionally, ROS is related to cartilage damage in OA [42]. Consistent with previous studies, the level of Gpx4 was decreased in the erastin-treated chondrocytes. In the presence of TF3, the decreased level of Gpx4 and lethal ROS accumulation were reversed in a concentration-dependent manner, suggesting the anti-liposome peroxidation ability of TF3.

Abnormal iron metabolism contributes to ferroptosis induced by the production of ROS from the Fenton reaction [35, 43]. Divalent metal transporter 1 (DMT1, also named Slc11a2) mediates the release of Fe^{2+} from the endosome into a labile iron pool in the cytoplasm [44]. Excess iron is stored in an iron storage protein complex including ferritin light chain (FTL) and ferritin heavy chain1 (FTH1) [45]. Increased iron uptake and reduced iron storage may contribute to iron overload during ferroptosis [46]. Consistently, our results showed that the level of Fe^{2+} was increased in the erastin-treated chondrocytes and reversed by addition of TF3. In addition, TF3 promoted FTH1 expression. These

observations suggested that TF3 inhibits ferroptosis by promoting iron metabolism in OA chondrocytes.

The mechanism of ferroptosis has not been fully elucidated. Cystine-glutamate antiporter (System Xc-) [47, 48], coenzyme Q (CoQ) [49], and ASCL4-related pathways have been involved in ferroptosis [50–52]. Slc7a11, a subunit unique to system Xc, inhibits intracellular GSH depletion, iron-dependent lipid peroxidation and subsequent ferroptosis [53]. Our study showed that TF3 elevates the expression of Slc7a11, suggesting that Slc7a11 mediates TF3 anti-ferroptosis effect.

Recently, growing attention has been given to the role of the Nrf2 transcription factor in cartilage homeostasis [54]. Nrf2 is capable of regulating the basal and inducible expression of a plethora of antioxidant and detoxification enzymes, including CAT, SOD, Gpxs, heme-oxygenase1 (HO-1), NADPH, and quinone oxidoreductase1 (NQO1) [55, 56]. Pharmacological activation of Nrf2 or overexpression of Nrf2 [57] has been shown to limit IL-1 β -induced reactive oxygen species generation and reduce the absorption of iron in chondrocytes, demonstrating the importance of Nrf2 activity on the antioxidant response in cartilage. We found that the MEK1/2, ERK1/2, and Keap1/Nrf2/Gpx4 signaling pathways were activated in erastin-treated chondrocytes in the presence of TF3. Under normal conditions, the DGR region of Keap1 binds to the DLG and ETGE sequences of Nrf2, which stabilizes Nrf2 in the cytoplasm and induces Nrf2 ubiquitination and proteasome degradation [58]. Keap1 transforms its connection with Nrf2 by sensing changes in ROS, promoting nucleus Nrf2 accumulation binding with the promoter antioxidant response element (ARE) to induce downstream antioxidant proteases transcription and translation [59]. The increased ROS level was associated with the elevated Nrf2 expression, by which cells maintain oxidative stress balance [60]. These studies were




FIGURE 7: TF3 diminishes cartilage destruction in OA rat model. SD rats were divided into five groups: Control, OA, OA + Erastin, OA + Erastin+TF3, OA + Erastin+DFO. (a) The representative visual inspection of cartilage damage and representative images is shown. The arrows point to the areas of medial femoral condyles. (b) The representative MRI results of rats. (c) The representative HE staining results of different groups. (d) The progression of OA was evaluated using the OARSI scores. * $p < 0.05$, ** $p < 0.01$. Statistical comparisons were calculated using the Mann-Whitney U test.

consistent with the observation that after the chondrocytes were stimulated by erastin, the expressions of Nrf2 in the nucleus and lipid ROS levels in chondrocytes were all markedly increased. After TF3 intervention, nucleus Nrf2 bound with the promoter ARE to induce Gpx4 expression, further scavenging lipid ROS. Further, knockdown of Nrf2 resulted in decreased expression of downstream targets (Slc7a11, Gpx4, FTH1, and HO-1), and TF3 did not completely reverse Gpx4 expression and erastin-induced chondrocyte

ferroptosis in Nrf2 knockdown cells. In further support, application of the Gpx4 inhibitor RSL3 [61] caused similar results to that of Nrf2 knockdown, such as elevated lipid peroxidation, decreased cell viability, and thus increased ferroptosis. However, when chondrocytes were pretreated with RSL3, TF3 could not reverse chondrocyte ferroptosis, strongly implicating that the protective effects of TF3 on cell viability were mediated via activation of Gpx4, which protects against ferroptosis. Thus, these results suggested that




FIGURE 8: TF3 increases proteoglycans and Gpx4 expression in a rat OA model. (a) The representative Masson staining results of proteoglycans expression in different groups are shown. (b) The representative immunohistochemistry staining of Gpx4 are shown. Arrowheads indicated positive cells. (c) The number of Gpx4 positive cells per field under 100-time magnification is shown. The data are presented as the mean \pm SD of three independent experiments, and statistical significance was determined by one-way ANOVA. * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$. DFO: deferoxamine.

the Nrf2/Gpx4-related pathway is a mediator of the protective effects of TF3 in OA chondrocytes.

Delaying articular cartilage degeneration was the key intervention method for OA treatment [62]. Systemic administration of DFO reduces cartilage lesion development

in the OA model [34]. Our animal experiments results showed that TF3 could alleviate the degeneration of OA cartilage, which was manifested by a lower OARSI score and lower degree of articular cartilage destruction. Meanwhile, TF3 notably upregulated the expression of proteoglycans

and anti-ferroptosis protein Gpx4. These *in vivo* results indicated the protective effect of TF3 on OA was similar to that of DFO.

5. Conclusions

In summary, we found that TF3 protects chondrocytes against erastin-induced ferroptosis via the Nrf2/Gpx4 signaling pathway activation, suggesting that TF3 might be a novel and promising therapeutic option for OA (graphical abstracts).

Abbreviations

OA:	Osteoarthritis
TCA:	Tricarboxylic acid cycle
AA:	Ascorbic acid
ROS:	Reactive oxygen species
MDA:	Malondialdehyde
SOD:	Peroxide dismutase
Gpx4:	Glutathione peroxidase 4
GSH:	Glutathione
TF3:	Theaflavin-3,3'-digallate
BMMs:	Bone marrow-derived macrophages
DFO:	Deferoxamine
OARSI:	Osteoarthritis research society international
DMEM:	Dulbecco's modified Eagle's medium
AA:	Ascorbic acid
RIPA:	Radioimmunoprecipitation assay buffer
PVDF:	Polyvinylidene fluoride
MRI:	Magnetic resonance imaging
EDTA:	Ethylenediaminetetraacetic acid
DMM:	Medial meniscus destabilization
Nrf2:	Nuclear factor erythroid 2-related factor 2
NSAIDs:	Nonsteroid anti-inflammatory drugs
DMT1:	Divalent metal transporter 1
FTL:	Ferritin light chain
FTH1:	Ferritin heavy chain 1
System Xc ⁻ :	Cystine-glutamate antitransporter
COQ:	Coenzyme Q
Slc7a11:	Light chain subunit of the cystine/glutamate anticarrier
NQO1:	NADPH quinone oxidoreductase 1
HO-1:	Heme-oxygenase 1
ARE:	Antioxidant response element.

Data Availability

The datasets used in the present study are available from the corresponding author on reasonable request.

Ethical Approval

The informed consent form was approved by the Nanjing Medical University Review Board (the file number is [2017] KY035-01).

Consent

All participants have signed the informed consent form prior to their participation in the study.

Conflicts of Interest

The authors declare that they are free from conflict of interest in presenting it.

Authors' Contributions

YW contributed to the conception and design of the study. NS, XC, YYY, and YGR carried out the principal experiments. XC and ZBJ completed the acquisition or preparation of clinical samples. ZGY, WLL, JSJ, XNW, and ZRX contributed to the analysis and interpretation of the data. XC contributed to the drafting of the article. YW contributed to the critical revision of important intellectual content. All authors read and approved the final manuscript.

Acknowledgments

This work was supported by grants from the National Natural Science Foundation of China (81171680 to Y.W.), the Science and Technology Support Program of Jiangsu Province (BE2015632 to Y.W.), the Changzhou Science and Technology Bureau (ZD202217 to Y.W., CJ20180057 to S.N., and WZ202204 to C.X.), the Natural Science Foundation of the Jiangsu for Youth (BK20180182 to S.N.), China Postdoctoral Science Foundation (2019M651898 to S.N.), Changzhou No. 2. People's Hospital Foundation (2022K004 to C.X.). We want to thank all the patients who participated in our study and Professors Xianju Zhou, Dawei Li, and Stephen Rudnik for giving suggestions.

Supplementary Materials

Table S1: the key information of all antibodies used in our study is listed, and the graphical abstracts are available in supplementary files. (*Supplementary Materials*)

References

- [1] N. E. Lane and M. Corr, "Anti-NGF treatments for pain – two steps forward, one step back?," *Nature Reviews Rheumatology*, vol. 13, no. 2, pp. 76–78, 2017.
- [2] S. Onuora, "UCMA links cartilage and bone in OA," *Nature Reviews Rheumatology*, vol. 13, no. 3, p. 130, 2017.
- [3] X. Yao, K. Sun, S. Yu et al., "Chondrocyte ferroptosis contribute to the progression of osteoarthritis," *Journal of Orthopaedic Translation*, vol. 27, pp. 33–43, 2021.
- [4] W. S. Yang and B. R. Stockwell, "Ferroptosis: death by lipid peroxidation," *Trends in Cell Biology*, vol. 26, no. 3, pp. 165–176, 2016.
- [5] Y. Li, D. Feng, Z. Wang et al., "Ischemia-induced ACSL4 activation contributes to ferroptosis-mediated tissue injury in intestinal ischemia/reperfusion," *Cell Death and Differentiation*, vol. 26, no. 11, pp. 2284–2299, 2019.
- [6] A. Southon, K. Szostak, K. M. Acevedo et al., "CuII(atms) inhibits ferroptosis: implications for treatment of neurodegenerative disease," *British Journal of Pharmacology*, vol. 177, no. 3, pp. 656–667, 2020.
- [7] Y. Wang, L. Yang, X. Zhang et al., "Epigenetic regulation of ferroptosis by H2B monoubiquitination and p53," *EMBO Reports*, vol. 20, no. 7, article e47563, 2019.

- [8] Y. Kawakami and N. K. Bhullar, "Potential implications of interactions between Fe and S on cereal Fe biofortification," *International Journal of Molecular Sciences*, vol. 21, no. 8, p. 2827, 2020.
- [9] J. Zhu, F. Yu, J. Meng et al., "Overlooked role of Fe(IV) and Fe(V) in organic contaminant oxidation by Fe(VI)," *Environmental Science & Technology*, vol. 54, no. 15, pp. 9702–9710, 2020.
- [10] S. A. Adefegha and G. Oboh, "In vitro inhibition activity of polyphenol-rich extracts from *Syzygium aromaticum* (L.) Merr. & Perry (clove) buds against carbohydrate hydrolyzing enzymes linked to type 2 diabetes and Fe²⁺-induced lipid peroxidation in rat pancreas," *Asian Pacific Journal of Tropical Biomedicine*, vol. 2, no. 10, pp. 774–781, 2012.
- [11] T. Takadera, Y. Koriyama, T. Kimura, and S. Kato, "5-S-GAD attenuates Fe²⁺-induced lipid peroxidation and cell death in a neuronal cell model," *Neurotoxicity Research*, vol. 20, no. 1, pp. 26–31, 2011.
- [12] C. Wu, W. Zhao, J. Yu, S. Li, L. Lin, and X. Chen, "Induction of ferroptosis and mitochondrial dysfunction by oxidative stress in PC12 cells," *Scientific Reports*, vol. 8, no. 1, p. 574, 2018.
- [13] M. K. Foret, S. Do Carmo, R. Lincoln et al., "Effect of antioxidant supplements on lipid peroxidation levels in primary cortical neuron cultures," *Free Radical Biology & Medicine*, vol. 130, pp. 471–477, 2019.
- [14] Y. Ai, B. Yan, and X. Wang, "The oxidoreductases POR and CYB5R1 catalyze lipid peroxidation to execute ferroptosis," *Molecular & Cellular Oncology*, vol. 8, no. 2, article 1881393, 2017.
- [15] M. M. Gaschler and B. R. Stockwell, "Lipid peroxidation in cell death," *Biochemical and Biophysical Research Communications*, vol. 482, no. 3, pp. 419–425, 2017.
- [16] S. Wei, T. Qiu, X. Yao et al., "Arsenic induces pancreatic dysfunction and ferroptosis via mitochondrial ROS-autophagy-lysosomal pathway," *Journal of Hazardous Materials*, vol. 384, article 121390, 2020.
- [17] F. Ursini and M. Maiorino, "Lipid peroxidation and ferroptosis: the role of GSH and GPx4," *Free Radical Biology & Medicine*, vol. 152, pp. 175–185, 2020.
- [18] H. Pan, E. Kim, G. O. Rankin, Y. Rojanasakul, Y. Tu, and Y. C. Chen, "Theaflavin-3,3'-digallate inhibits ovarian cancer stem cells via suppressing Wnt/ β -Catenin signaling pathway," *Journal of Functional Foods*, vol. 50, pp. 1–7, 2018.
- [19] G. Fu, H. Wang, Y. Cai, H. Zhao, and W. Fu, "Theaflavin alleviates inflammatory response and brain injury induced by cerebral hemorrhage via inhibiting the nuclear transcription factor kappa β -related pathway in rats," *Drug Design, Development and Therapy*, vol. Volume 12, pp. 1609–1619, 2018.
- [20] H. Wang, G. Wei, F. Liu et al., "Characterization of two homogalacturonan pectins with immunomodulatory activity from green tea," *International Journal of Molecular Sciences*, vol. 15, no. 6, pp. 9963–9978, 2014.
- [21] H. Pan, J. Li, G. O. Rankin, Y. Rojanasakul, Y. Tu, and Y. C. Chen, "Synergistic effect of black tea polyphenol, theaflavin-3,3'-digallate with cisplatin against cisplatin resistant human ovarian cancer cells," *Journal of Functional Foods*, vol. 46, pp. 1–11, 2018.
- [22] H. Pan, E. Kim, G. O. Rankin, Y. Rojanasakul, Y. Tu, and Y. Chen, "Theaflavin-3,3'-digallate enhances the inhibitory effect of cisplatin by regulating the copper transporter 1 and glutathione in human ovarian cancer cells," *International Journal of Molecular Sciences*, vol. 19, no. 1, p. 117, 2018.
- [23] X. Hu, Z. Ping, M. Gan et al., "Theaflavin-3,3'-digallate represses osteoclastogenesis and prevents wear debris-induced osteolysis via suppression of ERK pathway," *Acta Biomaterialia*, vol. 48, pp. 479–488, 2017.
- [24] Y. Tanaka, M. Kirita, Y. Abe et al., "Metabolic stability and inhibitory effect of O-methylated theaflavins on H₂O₂-induced oxidative damage in human HepG2 cells," *Bioscience, Biotechnology, and Biochemistry*, vol. 78, no. 7, pp. 1140–1146, 2014.
- [25] J. Li and J. Zheng, "Theaflavins prevent cartilage degeneration via AKT/FOXO3 signaling in vitro," *Molecular Medicine Reports*, vol. 19, no. 2, pp. 821–830, 2019.
- [26] J. Wu, A. M. Minikes, M. Gao et al., "Intercellular interaction dictates cancer cell ferroptosis via NF2-YAP signalling," *Nature*, vol. 572, no. 7769, pp. 402–406, 2019.
- [27] Z. Fan, A. K. Wirth, D. Chen et al., "Nrf2-Keap1 pathway promotes cell proliferation and diminishes ferroptosis," *Oncogenesis*, vol. 6, no. 8, article e371, 2017.
- [28] X. Wang, C. Zhang, N. Zou et al., "Lipocalin-2 silencing suppresses inflammation and oxidative stress of acute respiratory distress syndrome by ferroptosis via inhibition of MAPK/ERK pathway in neonatal mice," *Bioengineered*, vol. 13, no. 1, pp. 508–520, 2022.
- [29] H. Wang, S. Peng, J. Cai, and S. Bao, "Silencing of PTPN18 induced ferroptosis in endometrial cancer cells through p-P38-mediated GPX4/xCT down-regulation," *Cancer Management and Research*, vol. Volume 13, pp. 1757–1765, 2021.
- [30] Q. Liu and K. Wang, "The induction of ferroptosis by impairing STAT3/Nrf2/GPx4 signaling enhances the sensitivity of osteosarcoma cells to cisplatin," *Cell Biology International*, vol. 43, no. 11, pp. 1245–1256, 2019.
- [31] C. Chen, D. Wang, Y. Yu et al., "Legumain promotes tubular ferroptosis by facilitating chaperone-mediated autophagy of GPX4 in AKI," *Cell Death & Disease*, vol. 12, no. 1, p. 65, 2021.
- [32] K. Fujiki, H. Inamura, T. Sugaya, and M. Matsuoka, "Blockade of ALK4/5 signaling suppresses cadmium- and erastin-induced cell death in renal proximal tubular epithelial cells via distinct signaling mechanisms," *Cell Death and Differentiation*, vol. 26, no. 11, pp. 2371–2385, 2019.
- [33] H. F. Yan, T. Zou, Q. Z. Tuo et al., "Ferroptosis: mechanisms and links with diseases," *Signal Transduction and Targeted Therapy*, vol. 6, no. 1, p. 49, 2021.
- [34] L. H. Burton, M. F. Afzali, L. B. Radakovich et al., "Systemic administration of a pharmacologic iron chelator reduces cartilage lesion development in the Dunkin-Hartley model of primary osteoarthritis," *Free Radic Biol Med*, vol. 179, pp. 47–58, 2022.
- [35] C. Cai, W. Hu, and T. Chu, "Interplay between iron overload and osteoarthritis: clinical significance and cellular mechanisms," *Frontiers in Cell and Development Biology*, vol. 9, article 817104, 2021.
- [36] A. Datta, N. R. Flynn, D. A. Barnette, K. F. Woeltje, G. P. Miller, and S. J. Swamidass, "Machine learning liver-injuring drug interactions with non-steroidal anti-inflammatory drugs (NSAIDs) from a retrospective electronic health record (EHR) cohort," *PLoS Computational Biology*, vol. 17, no. 7, article e1009053, 2021.

- [37] L. Wang, Y. Liu, T. Du et al., "ATF3 promotes erastin-induced ferroptosis by suppressing system Xc⁻," *Cell Death and Differentiation*, vol. 27, no. 2, pp. 662–675, 2020.
- [38] Y. Li, X. Zeng, D. Lu, M. Yin, M. Shan, and Y. Gao, "Erastin induces ferroptosis via ferroportin-mediated iron accumulation in endometriosis," *Human Reproduction*, vol. 36, no. 4, pp. 951–964, 2021.
- [39] W. Sutipornpalangkul, N. P. Morales, K. Charoencholvanich, and T. Harnroongroj, "Lipid peroxidation, glutathione, vitamin E, and antioxidant enzymes in synovial fluid from patients with osteoarthritis," *International Journal of Rheumatic Diseases*, vol. 12, no. 4, pp. 324–328, 2009.
- [40] K. M. Surapneni and V. S. Chandrasada Gopan, "Lipid peroxidation and antioxidant status in patients with rheumatoid arthritis," *Indian Journal of Clinical Biochemistry*, vol. 23, no. 1, pp. 41–44, 2008.
- [41] H. Imai, M. Matsuoka, T. Kumagai, T. Sakamoto, and T. Koumura, "Lipid peroxidation-dependent cell death regulated by GPx4 and ferroptosis," *Current Topics in Microbiology and Immunology*, vol. 403, pp. 143–170, 2017.
- [42] J. A. Bolduc, J. A. Collins, and R. F. Loeser, "Reactive oxygen species, aging and articular cartilage homeostasis," *Free Radical Biology & Medicine*, vol. 132, pp. 73–82, 2019.
- [43] P. Fritz, J. G. Saal, C. Wicherek, A. König, W. Laschner, and H. Rautenstrauch, "Quantitative photometrical assessment of iron deposits in synovial membranes in different joint diseases," *Rheumatology International*, vol. 15, no. 5, pp. 211–216, 1996.
- [44] N. Montalbetti, A. Simonin, C. Simonin, M. Awale, J. L. Reymond, and M. A. Hediger, "Discovery and characterization of a novel non-competitive inhibitor of the divalent metal transporter DMT1/SLC11A2," *Biochemical Pharmacology*, vol. 96, no. 3, pp. 216–224, 2015.
- [45] G. Mesquita, T. Silva, A. C. Gomes et al., "H-ferritin is essential for macrophages' capacity to store or detoxify exogenously added iron," *Scientific Reports*, vol. 10, no. 1, p. 3061, 2020.
- [46] L. Yang, H. Wang, X. Yang et al., "Auranofin mitigates systemic iron overload and induces ferroptosis via distinct mechanisms," *Signal Transduction and Targeted Therapy*, vol. 5, no. 1, p. 138, 2020.
- [47] S. Doll, B. Proneth, Y. Y. Tyurina et al., "ACSL4 dictates ferroptosis sensitivity by shaping cellular lipid composition," *Nature Chemical Biology*, vol. 13, no. 1, pp. 91–98, 2017.
- [48] W. S. Yang, K. J. Kim, M. M. Gaschler, M. Patel, M. S. Shchepinov, and B. R. Stockwell, "Peroxidation of polyunsaturated fatty acids by lipoxygenases drives ferroptosis," *Proceedings of the National Academy of Sciences of the United States of America*, vol. 113, no. 34, pp. E4966–E4975, 2016.
- [49] K. Bersuker, J. M. Hendricks, Z. Li et al., "The CoQ oxidoreductase FSP1 acts parallel to GPX4 to inhibit ferroptosis," *Nature*, vol. 575, no. 7784, pp. 688–692, 2019.
- [50] X. Sun, Z. Ou, M. Xie et al., "HSPB1 as a novel regulator of ferroptotic cancer cell death," *Oncogene*, vol. 34, no. 45, pp. 5617–5625, 2015.
- [51] S. Li, L. Zheng, J. Zhang, X. Liu, and Z. Wu, "Inhibition of ferroptosis by up-regulating Nrf2 delayed the progression of diabetic nephropathy," *Free Radical Biology & Medicine*, vol. 162, pp. 435–449, 2021.
- [52] B. R. Stockwell, J. P. Friedmann Angeli, H. Bayir et al., "Ferroptosis: a regulated cell death nexus linking metabolism, redox biology, and disease," *Cell*, vol. 171, no. 2, pp. 273–285, 2017.
- [53] J. Lewerenz, S. J. Hewett, Y. Huang et al., "The cystine/glutamate antiporter system x(c)⁻ in health and disease: from molecular mechanisms to novel therapeutic opportunities," *Antioxidants & Redox Signaling*, vol. 18, no. 5, pp. 522–555, 2013.
- [54] K. Sun, J. Luo, X. Jing et al., "Astaxanthin protects against osteoarthritis via Nrf2: a guardian of cartilage homeostasis," *Aging (Albany NY)*, vol. 11, no. 22, pp. 10513–10531, 2019.
- [55] Y. Zhuang, H. Wu, X. Wang, J. He, S. He, and Y. Yin, "Resveratrol attenuates oxidative stress-induced intestinal barrier injury through PI3K/Akt-mediated Nrf2 signaling pathway," *Oxidative Medicine and Cellular Longevity*, vol. 2019, Article ID 7591840, 14 pages, 2019.
- [56] Y. Hao, J. Miao, W. Liu, L. Peng, Y. Chen, and Q. Zhong, "Formononetin protects against cisplatin-induced acute kidney injury through activation of the PPAR α /Nrf2/HO-1/NQO1 pathway," *International Journal of Molecular Medicine*, vol. 47, no. 2, pp. 511–522, 2021.
- [57] N. M. Khan, I. Ahmad, and T. M. Haqqi, "Nrf2/ARE pathway attenuates oxidative and apoptotic response in human osteoarthritis chondrocytes by activating ERK1/2/ELK1-P70S6K-P90RSK signaling axis," *Free Radical Biology & Medicine*, vol. 116, pp. 159–171, 2018.
- [58] A. S. Marchev, P. A. Dimitrova, A. J. Burns, R. V. Kostov, A. T. Dinkova-Kostova, and M. I. Georgiev, "Oxidative stress and chronic inflammation in osteoarthritis: can NRF2 counteract these partners in crime?," *Annals of the New York Academy of Sciences*, vol. 1401, no. 1, pp. 114–135, 2017.
- [59] T. Suzuki and M. Yamamoto, "Molecular basis of the Keap1-Nrf2 system," *Free Radical Biology & Medicine*, vol. 88, pp. 93–100, 2015.
- [60] M. C. Lu, J. A. Ji, Z. Y. Jiang, and Q. D. You, "The Keap1-Nrf2-ARE pathway as a potential preventive and therapeutic target: an update," *Medicinal Research Reviews*, vol. 36, no. 5, pp. 924–963, 2016.
- [61] M. Gryzik, M. Asperti, A. Denardo, P. Arosio, and M. Poli, "NCOA4-mediated ferritinophagy promotes ferroptosis induced by erastin, but not by RSL3 in HeLa cells," *Biochimica et Biophysica Acta (BBA) - Molecular Cell Research*, vol. 1868, no. 2, article 118913, 2021.
- [62] M. Varela-Eirin, J. Loureiro, E. Fonseca et al., "Cartilage regeneration and ageing: targeting cellular plasticity in osteoarthritis," *Ageing Research Reviews*, vol. 42, pp. 56–71, 2018.